homovanillic acid has been researched along with Dissociation in 2 studies
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.
homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.
homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ketamine (1) produced behaviors similar to the positive and negative symptoms of schizophrenia; (2) elicited alterations in perception; (3) impaired performance on tests of vigilance, verbal fluency, and the Wisconsin Card Sorting Test; (4) evoked symptoms similar to dissociative states; and (5) preferentially disrupted delayed word recall, sparing immediate recall and postdistraction recall." | 5.07 | Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. ( Bowers, MB; Bremner, JD; Charney, DS; Delaney, R; Freeman, GK; Heninger, GR; Karper, LP; Krystal, JH; Seibyl, JP, 1994) |
| " In this study, we examined cerebrospinal fluid levels of the major monoamine metabolites and beta-endorphin in patients with eating disorders (11 with anorexia nervosa, 16 with bulimia nervosa), while they were acutely ill." | 3.68 | Relation of dissociative phenomena to levels of cerebrospinal fluid monoamine metabolites and beta-endorphin in patients with eating disorders: a pilot study. ( Altemus, M; Demitrack, MA; Gold, PW; Krahn, DD; Pigott, TA; Putnam, FW; Rubinow, DR, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Demitrack, MA | 1 |
| Putnam, FW | 1 |
| Rubinow, DR | 1 |
| Pigott, TA | 1 |
| Altemus, M | 1 |
| Krahn, DD | 1 |
| Gold, PW | 1 |
| Krystal, JH | 1 |
| Karper, LP | 1 |
| Seibyl, JP | 1 |
| Freeman, GK | 1 |
| Delaney, R | 1 |
| Bremner, JD | 1 |
| Heninger, GR | 1 |
| Bowers, MB | 1 |
| Charney, DS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder[NCT03748446] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2019-12-05 | Recruiting | ||
| Efficacy of Rapid-Acting NMDA Antagonist for Treatment of Adolescent Depression and Anxiety Disorders[NCT02579928] | Phase 4 | 17 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Measurement of GABA and Neurosteroid Levels in Women With Menopausal Major Depression Before and After Treatment With Estrogen Alone, Fluoxetine Alone, or Estrogen and Fluoxetine and Normal Controls Before and After Treatment With Estrogen[NCT00626340] | Phase 4 | 18 participants (Actual) | Interventional | 1999-07-31 | Completed | ||
| Changes of the Short Portable Mental Status Questionnaire (SPMSQ-E) After Ketamine Administration on Ophthalmic Surgery in Geriatric Population.[NCT02049411] | Phase 2 | 80 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia[NCT03323437] | Phase 4 | 47 participants (Actual) | Interventional | 2017-09-15 | Completed | ||
| Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy[NCT03889756] | Phase 2/Phase 3 | 3 participants (Actual) | Interventional | 2019-07-17 | Terminated (stopped due to No more funding available to continue since we could not recruit throughout the pandemic.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Depressive symptoms (measured by Montgomery-Asberg Depression Rating Scale, revised (MADRS) score) on 1 day after infusion, for the cohort of subjects enrolled in the MDD arm of this trial.~Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60.~Usual cutoff points are:~0 to 6 - normal /symptom absent. 7 to 19 - mild depression. 20 to 34 - moderate depression. >34 - severe depression." (NCT02579928)
Timeframe: 1 day after the infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 15.44 |
| Midazolam | 24.13 |
"This study was conducted at Yale University almost two decades ago. Our group at the University of Pennsylvania only has very basic information about this study. This includes the number of participants, which was 18, and the fact that no adverse events occurred. Staff members at the University of Pennsylvania do not have access to any additional study data. The contact person who initially entered this study protocol information is no longer at the University of Pennsylvania and we are unable to contact for additional information.~We only know that 18 participants completed, but as far as we know data was never analyzed for these 18 participants." (NCT00626340)
Timeframe: Healthy controls will undergo scans pre and post 3 weeks of estrogen treatment. Women with depression will undergo scans pre and post 6 weeks of treatment with estrogen alone, estrogen and fluoxetine, or fluoxetine alone
| Intervention | () |
|---|---|
| All Participants | 0 |
Establish if repeated ketamine will be efficacious medically and psychiatrically, as measured by a significant reduction in CDRS score in those treated with ketamine at the end of the dosing paradigm. The Children's Depression Rating Scale (CDRS) is a clinician-rated instrument with 17 items scored on a 1 to 5 or 1 to 7 scale. A rating of 1 indicates normal, thus the minimum score is 17. The maximum score is 113. Scores of 20-30 suggest borderline depression. Scores of 40-60 indicate moderate depression. (NCT03889756)
Timeframe: Day 18
| Intervention | score on a scale (Mean) |
|---|---|
| Ketamine | 42 |
| Midazolam | 62 |
Establish if repeated ketamine will be tolerated as measured by drop-out counts. (NCT03889756)
Timeframe: Day 18
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine | 0 |
| Midazolam | 0 |
1 trial available for homovanillic acid and Dissociation
| Article | Year |
|---|---|
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
1 other study available for homovanillic acid and Dissociation
| Article | Year |
|---|---|
Relation of dissociative phenomena to levels of cerebrospinal fluid monoamine metabolites and beta-endorphin in patients with eating disorders: a pilot study.
Topics: Adolescent; Adult; Anorexia Nervosa; beta-Endorphin; Body Weight; Brain; Bulimia; Dissociative Disor | 1993 |